doi: 10.1155/2023/9823491.
eCollection 2023.
Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
- PMID: 37416219
- PMCID: PMC10322360
- DOI: 10.1155/2023/9823491
Item in Clipboard
Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
Comput Math Methods Med.
.
Abstract
[This retracts the article DOI: 10.1155/2022/4600145.].
Copyright © 2023 Computational and Mathematical Methods in Medicine.
Retraction of
-
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.Comput Math Methods Med. 2022 Jun 10;2022:4600145. doi: 10.1155/2022/4600145. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Jun 28;2023:9823491. doi: 10.1155/2023/9823491. PMID: 35720032 Free PMC article. Retracted.
Similar articles
-
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.Comput Math Methods Med. 2022 Jun 10;2022:4600145. doi: 10.1155/2022/4600145. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Jun 28;2023:9823491. doi: 10.1155/2023/9823491. PMID: 35720032 Free PMC article. Retracted.
-
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.Anticancer Res. 2023 Mar;43(3):1265-1272. doi: 10.21873/anticanres.16273. Anticancer Res. 2023. PMID: 36854492
-
Treatment of recurrent ovarian cancer.Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. Ann Oncol. 2017. PMID: 29232464 Review.
-
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.Gynecol Oncol. 2023 Mar;170:241-247. doi: 10.1016/j.ygyno.2023.01.020. Epub 2023 Feb 1. Gynecol Oncol. 2023. PMID: 36736157
-
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.Bull Cancer. 2021 Dec;108(9S1):S22-S32. doi: 10.1016/S0007-4551(21)00584-1. Bull Cancer. 2021. PMID: 34955159 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
